Caseware UK (AP4) 2025.0.111 2025.0.111 2026-03-312026-03-31true2025-04-01falseNo description of principal activity77falsefalse 11243462 2025-04-01 2026-03-31 11243462 2024-04-01 2025-03-31 11243462 2026-03-31 11243462 2025-03-31 11243462 1 2025-04-01 2026-03-31 11243462 d:Director5 2025-04-01 2026-03-31 11243462 c:FurnitureFittings 2025-04-01 2026-03-31 11243462 c:FurnitureFittings 2026-03-31 11243462 c:FurnitureFittings 2025-03-31 11243462 c:FurnitureFittings c:OwnedOrFreeholdAssets 2025-04-01 2026-03-31 11243462 c:ComputerEquipment 2025-04-01 2026-03-31 11243462 c:ComputerEquipment 2026-03-31 11243462 c:ComputerEquipment 2025-03-31 11243462 c:ComputerEquipment c:OwnedOrFreeholdAssets 2025-04-01 2026-03-31 11243462 c:OtherPropertyPlantEquipment 2025-04-01 2026-03-31 11243462 c:OtherPropertyPlantEquipment 2026-03-31 11243462 c:OtherPropertyPlantEquipment 2025-03-31 11243462 c:OtherPropertyPlantEquipment c:OwnedOrFreeholdAssets 2025-04-01 2026-03-31 11243462 c:OwnedOrFreeholdAssets 2025-04-01 2026-03-31 11243462 c:CurrentFinancialInstruments 2026-03-31 11243462 c:CurrentFinancialInstruments 2025-03-31 11243462 c:CurrentFinancialInstruments c:WithinOneYear 2026-03-31 11243462 c:CurrentFinancialInstruments c:WithinOneYear 2025-03-31 11243462 c:ShareCapital 2026-03-31 11243462 c:ShareCapital 2025-03-31 11243462 c:SharePremium 2026-03-31 11243462 c:SharePremium 2025-03-31 11243462 c:OtherMiscellaneousReserve 2026-03-31 11243462 c:OtherMiscellaneousReserve 2025-03-31 11243462 c:RetainedEarningsAccumulatedLosses 2026-03-31 11243462 c:RetainedEarningsAccumulatedLosses 2025-03-31 11243462 d:OrdinaryShareClass1 2025-04-01 2026-03-31 11243462 d:OrdinaryShareClass1 2026-03-31 11243462 d:OrdinaryShareClass1 2025-03-31 11243462 d:FRS102 2025-04-01 2026-03-31 11243462 d:Audited 2025-04-01 2026-03-31 11243462 d:FullAccounts 2025-04-01 2026-03-31 11243462 d:PrivateLimitedCompanyLtd 2025-04-01 2026-03-31 11243462 d:SmallCompaniesRegimeForAccounts 2025-04-01 2026-03-31 11243462 2 2025-04-01 2026-03-31 11243462 e:PoundSterling 2025-04-01 2026-03-31 iso4217:GBP xbrli:shares xbrli:pure

Registered number: 11243462










SUGAROX LIMITED










FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 MARCH 2026

 
SUGAROX LIMITED
REGISTERED NUMBER: 11243462

BALANCE SHEET
AS AT 31 MARCH 2026

As restated
2026
2025
Note
£
£

Fixed assets
  

Tangible fixed assets
  
2,632
2,024

  
2,632
2,024

Current assets
  

Debtors within one year
 6 
547,110
543,801

Cash at bank and in hand
  
356,766
455,374

  
903,876
999,175

Creditors: amounts falling due within one year
 7 
(134,930)
(100,696)

Net current assets
  
 
 
768,946
 
 
898,479

  

Net assets
  
771,578
900,503


Capital and reserves
  

Called up share capital 
 8 
196
184

Share premium account
  
2,700,130
2,299,950

Share-based payment reserve
  
369,297
151,536

Profit and loss account
  
(2,298,045)
(1,551,167)

  
771,578
900,503


The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




M I Robbins
Director

Date: 7 August 2026

The notes on pages 2 to 8 form part of these financial statements.

Page 1

 
SUGAROX LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

1.


General information

SugarOx Limited is a private company limited by shares and incorporated in England and Wales. Its registered office is:

Office 105, Russell Building
West Common
Harpenden
Hertfordshire
AL5 2JQ

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The level of rounding applied to figures presented throughout the financial statements is to the nearest pound. 

The following principal accounting policies have been applied:

  
2.2

Going concern

During the year ended 31 March 2026, the Company made a loss of £746,878 (2025: £436,897) and had net assets as at 31 March 2026 of £771,578 (2025: £900,503), including cash of £356,766 (2025: £455,374).

Notwithstanding these results for the year, during this stage of its lifecycle the Company is likely to remain in a net cash outflow position until such time as field trials have generated the positive results the Directors anticipate which will lead to full commercialisation of the Company’s developments.

The Directors recognise that further investment will be required to successfully complete the programme of research and development and enter products into full commercialisation.

The Company has a target for a Series A fundraise and in April 2026 received a commitment from a strategic partner for up to £2,500,000 receivable over 10 months by way of a Simple Agreement for Future Equity. The Company has also been successful in being awarded grants and will continue this strategy to complement its fundraising activities. 

The Directors have prepared budgets for a period of at least 12 months from approval of these financial statements. The Directors consider the budgets to be achievable and have assessed that the Company's cash flows remain positive through to March 2028 without the need for further equity fundraising in the period of 12 months from approval of these financial statements. Therefore, the Directors continue to prepare the financial statements on the going concern basis.
Page 2

 
SUGAROX LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

2.Accounting policies (continued)

 
2.3

Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

  
2.4

Borrowing costs

All borrowing costs are recognised in the profit and loss account in the period in which they are incurred.

 
2.5

Operating leases: the Company as lessee

Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term.

 
2.6

Interest income

Interest income is recognised in profit or loss using the effective interest method.

  
2.7

Grant income

Grant income has been recognised under the accrual model, where income is recognised on a systematic basis over the periods in which the entity recognises the related costs for which the grant is intended to compensate.

 
2.8

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in other creditors as a liability in the Balance Sheet. The assets of the plan are held separately from the Company in independently administered funds.

Page 3

 
SUGAROX LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

2.Accounting policies (continued)

 
2.9

Share-based payments

Where share options are awarded to employees, the fair value of the options at the date of grant is charged to profit or loss over the vesting period. Non-market vesting conditions are taken into account by adjusting the number of equity instruments expected to vest at each balance sheet date so that, ultimately, the cumulative amount recognised over the vesting period is based on the number of options that eventually vest.

The fair value of the award also takes into account non-vesting conditions. These are either factors beyond the control of either party (such as a target based on an index) or factors which are within the control of one or other of the parties (such as the Company keeping the scheme open or the employee maintaining any contributions required by the scheme).

Where the terms and conditions of options are modified before they vest, the increase in the fair value of the options, measured immediately before and after the modification, is also charged to profit or loss over the remaining vesting period.

Where equity instruments are granted to persons other than employees, profit or loss is charged with fair value of goods and services received.

 
2.10

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


 
2.11

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Page 4

 
SUGAROX LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

2.Accounting policies (continued)


2.11
Tangible fixed assets (continued)

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Fixtures and fittings
-
33%
Computer equipment
-
33%
Websites
-
33%

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.12

Debtors

Short-term debtors are measured at transaction price, less any impairment.

 
2.13

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.14

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

  
2.15

Impairment of non-financial assets

At each reporting date non-financial assets not carried at fair value, like goodwill and plant, property and equipment, are reviewed to determine whether there is an indication that an asset may be impaired. If there is an indication of possible impairment, the recoverable amount of any asset or group of related assets (which is the higher of value in use and the fair value less cost to sell) is estimated and compared with its carrying amount. If the recoverable amount is lower, the carrying amount of the asset is reduced to its recoverable amount and an impairment loss is recognised immediately in the profit and loss account.

If an impairment loss is subsequently reversed, the carrying amount of the asset, or group of related assets, is increased to the revised estimate of its recoverable amount, but not to exceed the amount that would have been determined had no impairment loss been recognised for the asset, or group of related assets, in prior periods. A reversal of an impairment loss is recognised immediately in the profit and loss account..

  
2.16

Research and development

Expenditure on research and development is written off against profits in the year in which it is incurred.

Page 5

 
SUGAROX LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

2.Accounting policies (continued)


3.


Critical accounting etimates and judgements

The Company makes estimates and assumptions concerning the future and judgements in applying the Company's accounting policies. The resulting accounting estimates will, by definition, seldom equal the actual results. 

The following estimates have had the most significant effect on the amounts recognised in the financial statements. 

Share based payment

The fair value of the share options at the date of grant is determined using the Black-Scholes model. This model uses key assumptions including the risk-free rate, share price and volatility of the share price. The fair value of the options at the date of grant is then charged to the Statement of Comprehensive Income over the vesting period. Non-market vesting conditions are taken into account by adjusting the number of equity instruments expected to vest at each Balance Sheet date so that ultimately the cumulative amount recognised over the vesting period is based on the number of options that eventually vest.


4.


Employees

The average monthly number of employees, including directors, during the year was 7 (2025 - 7).


5.


Tangible fixed assets


Fixtures and fittings
Computer equipment
Website
Total

£
£
£
£



Cost 


At 1 April 2025
3,209
3,113
1,000
7,322


Additions
-
2,415
-
2,415



At 31 March 2026

3,209
5,528
1,000
9,737



Depreciation


At 1 April 2025
2,230
2,068
1,000
5,298


Charge for the year on owned assets
979
828
-
1,807



At 31 March 2026

3,209
2,896
1,000
7,105



Net book value



At 31 March 2026
-
2,632
-
2,632



At 31 March 2025
979
1,045
-
2,024

Page 6

 
SUGAROX LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

6.


Debtors

2026
2025
£
£


Other debtors
44,498
45,586

Prepayments and accrued income
188,446
290,900

Tax recoverable
314,166
207,315

547,110
543,801



7.


Creditors: Amounts falling due within one year

2026
2025
£
£

Trade creditors
93,144
61,551

Other taxation and social security
11,785
21,202

Accruals and deferred income
30,001
17,943

134,930
100,696



8.


Share capital

2026
2025
£
£
Authorised, allotted, called up and fully paid



19,623 (2025 - 18,439) Ordinary shares of £0.01 each
196
184


During the year the Company alloted 1,184 (2025: 1655) Ordinary shares of £0.01 each for a total consideration of £400,192 (2025: £559,633) of which £nil (2025: £nil) was unpaid at the year end.


9.


Related party transactions

During the year, M Robbins, a director of the Company, provided consultancy services and recharged expenses through Cereja Life Sciences SL of £47,658 to the Company (2025: £47,600). At the year end, £4,178 was outstanding and is included in creditors due within one year (2025: £4,100).


10.


Controlling party

There is no one ultimate controlling party.


11.


Post balance sheet events

In April 2026, the Company raised additional investment of up to £2,500,000 under a Simple Agreement for Future Equity. 

Page 7

 
SUGAROX LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

12.


Auditor's information

The auditor's report on the financial statements for the year ended 31 March 2026 was unqualified.

The audit report was signed on 7 August 2026 by Samuel Britton FCCA (Senior Statutory Auditor) on behalf of James Cowper Kreston Audit.

Page 8